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Case presentation:1 
The patient was a 23-year-old man referred to the 
emergency department (ED) with the chief com-
plaint of palpitation. The patient experienced dizzi-
ness, cold sweating, and lightheadedness after get-
ting up which started spontaneously. He had four 
episodes of the same problems in seven months ago 
that felt better after taking 10 mg propranolol. 
However, in the current episode his problem was 
not solved by the same medication. He had no histo-
ry of smoking, substance abuse, medication use, 
congenital heart disease, syncope, previous surgery, 
chest trauma, or any other known medical prob-
lems. As well, he had no any positive history of the 
same problems in his family. The patients’ on-
arrival vital signs were as follow: systolic blood 
pressure (SBP): 90 mmHg, pulse rate (PR): 
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150/minute, respiratory rate (RR): 14/minute, oral 
temperature: 37◦C, oxygen saturation 96% with 
nasal cannula and 100% oxygen, Glasgow coma 
scale (GCS) 15/15. He was not experienced any oth-
er concomitant problems such as ischemic chest 
discomfort, shortness of breathing, or sign of circu-
latory shock such as paleness, mottling, etc. On gen-
eral physical examination the patients’ lung and 
heart sounds, four limbs pulses, and capillary refile 
were normal. As well, focused neurological and ab-
dominal examinations did not have any positive 
finding. The patient underwent close cardiac, vital 
sign monitoring and electrocardiography (ECG). 
Figure 1 shows the on-arrival patients’ ECG. Atrial 
fibrillation (AF) was diagnosed by the correspond-
ing physician and digoxin (!?) prescribed that led to 
severe lethargy, weakness, sweating, and bradycar-
dia. Figure 2 shows the post mediation ECG of pa-
tient. 
 
What is your diagnosis? 
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Diagnosis:  





The patient was admitted to CCU and after admin-
istration of Procainamide, his symptoms revealed 
(Figure 3) and he was sent for catheter ablation.  
Discussion: 
According to American Heart Association (AHA) 
2010 guideline for cardiopulmonary resuscitation 
(CPR), if the patient who manifested by tachycardia 
is presented with sever signs and symptoms includ-
ing ischemic chest discomfort, acute heart failure, 
acute altered mental status, sustain hypotension or 
other signs of shock, considered as unstable case 
and needs immediate cardioversion. However, in 
other symptomatic stable ones the subject present-
ed with irregular wide complex tachycardia, then 
avoiding atrioventricular (AV) nodal blocking agent 
is crucial. These agents such as β-adrenergic block-
ers, calcium channel blockers, and Digitalis (sum-
marized as BCD drugs) will not be effective, cannot 
block the conduction over the accessory pathway, 
and may even enhance conduction in hypotension 
or other dangerous outcomes such as ventricular 
fibrillation (VF) and cardiac arrest. Consequently, 
these drugs are contraindicated in such situations. 
Lidocaine is not useful for this purpose and may 
rarely exacerbate the conduction. Intravenous Pro-
cainamide is the treatment of choice and amioda-
rone may be a favorable second option in spite of 
some opposite literatures. Patients, who are hemo-
dynamically unstable, clearly require electrical car-
dioversion following current instructions (1-3). 
Wolff-Parkinson-White (WPW) syndrome is used 
for pre-excitation on ECG accompanied by paroxys-
mal tachycardia that may be conducted antegrade 
over the normal AV system or retrograde through 
the accessory pathway (AP). Antegrade type is char-
acterized by normal and narrow QRS complexes, 
regular rhythm, ventricular rate of 150-250 
beats/minutes, and sudden onset and abrupt termi-
nation. The classic electrocardiographic presenta-
tion of WPW syndrome consists of short PR interval, 
slurred and thickened initial upstroke of the QRS 
complex which is termed as delta wave, relatively 
normal-narrow terminal QRS defluxion which some-
times referred as the main QRS defluxion, Slight 
widening of the QRS defluxion, and secondary ST 
segment and T wave changes (4, 5). 
Although the incidence of dysrhythmias in WPW 
cases is rare, approximately 80% of dysrhythmias 
are AV reentrant tachycardia, 15-30% atrial fibrilla-
tion (AF), and 5% atrial flutter. AF is considered as 
an emergent situation when rapid antegrade con-
duction over an AP occurs in WPW syndrome. Clues 
in the ECG that may help suggesting WPW+AF in-
clude rhythm irregularity, a rapid ventricular re-
sponse (often with R-R intervals approaching 300 
beats/minutes), wide, and bizarre QRS complexes 
(6, 7). 
Szumowski et al. found that age, gender, and the 
history of syncope are independent risk factors of 
AF in patients with WPW syndrome and also men-
tioned that antegrade conduction via AP has a major 
importance in the development of AF (8). Hamada et 
al. mentioned that there are two mechanisms of 
paroxysmal AF in patients with WPW syndrome: 
one mechanism is reversible and AP-dependent 
atrial vulnerability, and the other one is intrinsic 
and AP-independent atrial vulnerability (9). 
During AF developing, the custom rate-limiting im-
pression of the AV node will be bypassed, and the 
consecutive excessive ventricular rates (even 200-
240 beats/minutes) may lead to disastrous conse-
quences such as ventricular fibrillation (VF), synco-
pe, and sudden death. Those who have survived 
from VF dysrhythmia, presented a rapid pre-excited 
ventricular response as it was demonstrated during 
the induction of AF in electrophysiological study (2). 
Sudden cardiac death and other possible dangerous 
outcomes in patients suffer from symptomatic ar-
rhythmias can be preventable. If they are enable to 
tolerate a rapid pre-excited ventricular response 
during AF (shortest pre-excited RR interval is less 
than 260 ms), accessory pathway catheter ablation 
or administration of antiarrhythmic drugs should be 
considered instead of such an invasive method to 
prevent conduction over the accessory pathway (2, 
3). 
It could be concluded that sometimes no cure is bet-
 
Figure 3  
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ter than wrong treatment. Without hurry, consult-
ant with other colleagues and adhering to present 
guidelines in approach to dysrhythmias can be help-
ful and even lifesaving. 
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